Ilka Thomsen

Ilka Thomsen

Auto-generated profile, based on publicly available information

Ilka Thomsen

Institute of Biochemistry, Christian-Albrechts-University Kiel, Kiel, Germany 1

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2021 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
JBJulia Bolik
Julia Bolik
FKFreia Krause
Freia Krause
MSMarija Stevanovic
Marija Stevanovic
MGMonja Gandraß
Monja Gandraß
ITIlka Thomsen
Ilka Thomsen
Dirk Schmidt-ArrasDirk Schmidt-Arras
Dirk Schmidt-Arras
Metastasis is the major cause of death in cancer patients. Circulating tumor cells need to migrate through the endothelial layer of blood vessels to escape the hostile circulation and establish metastases at distant organ sites. Here, we identified the membrane-bound metalloprotease ADAM17 on endothelial cells as a key driver of metastasis. We show that TNFR1-dependent tumor cell–induced endothelial cell death, tumor cell extravasation, and subsequent metastatic seeding is dependent on the activity of endothelial ADAM17. Moreover, we reveal that ADAM17-mediated TNFR1 ectodomain shedding and subsequent processing by the γ-secretase complex is required for the induction of TNF-induced necroptosis. Consequently, genetic ablation of ADAM17 in endothelial cells as well as short-term pharmacological inhibition of ADAM17 prevents long-term metastases formation in the lung. Thus, our data identified ADAM17 as a novel essential regulator of necroptosis and as a new promising target for antimetastatic and advanced-stage cancer therapies.